Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: Effects of treatment with valproic acid

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 8, 2011, Pages 850-852

  Piepers, Sanne ^a   Cobben, Jan Maarten ^b   Sodaar, Peter ^a   Jansen, Marc D ^a   Wadman, Renske I ^a   Meester Delver, Ann ^b   Poll The, Bwee Tien ^b   Lemmink, Henny H ^c   Wokke, John H J ^a   Van Der Pol, W Ludo ^a   Van Den Berg, Leonard H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVAL MOTOR NEURON PROTEIN; VALPROIC ACID;

ADOLESCENT; ARTICLE; CALIBRATION; CELL IMMORTALIZATION; CELL LINE; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOCYTE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHOOL CHILD; SPINAL MUSCULAR ATROPHY; UNSPECIFIED SIDE EFFECT;

EID: 79960141504     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.200253     Document Type: Article

References (15)

1. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-65.
2. Sumner CJ, Kolb SJ, Harmison GG, et al. SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 2006;66:1067-73. (Pubitemid 44044793)
3. Lefebvre S, Burlet P, Liu Q, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997;16:265-9. (Pubitemid 27280210)
4. Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003;54:647-54. (Pubitemid 37346071)
5. Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003;12:2481-9. (Pubitemid 37220412)
6. Brichta L, Holker I, Haug K, et al. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 2006;59:970-5.
7. Nguyen thi M, Humphrey E, Lam LT, et al. A two-site ELISA can quantify upregulation of SMN protein by drugs for spinal muscular atrophy. Neurology 2008;71:1757-63.
8. Tomaszewicz K, Kang P, Wu BL. Detection of homozygous and heterozygous SMN deletions of spinal muscular atrophy in a single assay with multiplex ligation-dependent probe amplification 41. Beijing Da Xue Xue Bao 2005;37:55-7.
9. Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009;4:-5268.
10. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006;67:500-1. (Pubitemid 44214981)
11. Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995;52:518-23.
12. Deymeer F, Serdaroglu P, Parman Y, et al. Natural history of SMA IIIb: muscle strength decreases in a predictable sequence and magnitude. Neurology 2008;71:644-9.
13. Kolb SJ, Gubitz AK, Olszewski RF Jr, et al. A novel cell immunoassay to measure survival of motor neurons protein in blood cells. BMC Neurol 2006;6:6.
14. Harada Y, Sutomo R, Sadewa AH, et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. J Neurol 2002;249:1211-19. (Pubitemid 35025095)
15. Hauke J, Riessland M, Lunke S, et al. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet 2009;18:304-17.